Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CDKN2A over exp SMARCB1 neg |
Therapy | Palbociclib |
Indication/Tumor Type | rhabdoid cancer |
Response Type | decreased response |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDKN2A over exp SMARCB1 neg | rhabdoid cancer | decreased response | Palbociclib | Preclinical | Actionable | In a preclinical study, CDKN2A (p16) over expression was associated with decreased sensitivity to Ibrance (palbociclib) in a SMARCB1-negative malignant rhabdoid tumor cell line in culture (PMID: 21871868). | 21871868 |
PubMed Id | Reference Title | Details |
---|---|---|
(21871868) | Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. | Full reference... |